Multiparametric MRI assessment of renal structure and function in acute kidney injury and renal recovery by Francis, Susan et al.
O R I G I N A L A R T I C L E
Multiparametric MRI assessment of renal structure and
function in acute kidney injury and renal recovery
Charlotte Buchanan 1, Huda Mahmoud2, Eleanor Cox1, Rebecca Noble2,
Benjamin Prestwich1, Isma Kasmi2, Maarten W. Taal2, Susan Francis1,3,* and
Nicholas M. Selby 2,*
1Sir Peter Mansfield Imaging Centre, School of Physics and Astronomy, University of Nottingham,
Nottingham, UK, 2Centre for Kidney Research and Innovation, University of Nottingham, Royal Derby
Hospital Campus, Nottingham, UK and 3National Institute for Health Research (NIHR), Nottingham
Biomedical Research Centre, Nottingham, UK
*Joint senior authors.
Correspondence to: Susan Francis; E-mail: susan.francis@nottingham.ac.uk
ABSTRACT
Background. Acute kidney injury (AKI) is associated with a marked increase in mortality as well as subsequent chronic
kidney disease (CKD) and end-stage kidney disease. We performed multiparametric magnetic resonance imaging (MRI) with
the aim of identifying potential non-invasive MRI markers of renal pathophysiology in AKI and during recovery.
Methods. Nine participants underwent inpatient MRI scans at time of AKI; seven had follow-up scans at 3 months and 1 year
following AKI. Multiparametric renal MRI assessed total kidney volume (TKV), renal perfusion using arterial spin labelling,
T1 mapping and blood oxygen level-dependent (BOLD) R2* mapping.
Results. Serum creatinine concentration had recovered to baseline levels at 1-year post-AKI in all participants. At the time of
AKI, participants had increased TKV, increased cortex/medulla T1 and reduced cortical perfusion compared with the
expected ranges in healthy volunteers and people with CKD. TKV and T1 values decreased over time after AKI and returned
to expected values in most but not all patients by 1 year. Cortical perfusion improved to a lesser extent and remained below
the expected range in the majority of patients by 1-year post-AKI. BOLD R2* data showed a non-significant trend to increase
over time post-AKI.
Conclusions. We observed a substantial increase in TKV and T1 during AKI and a marked decrease in cortical perfusion.
Despite biochemical recovery at 1-year post-AKI, MRI measures indicated persisting abnormalities in some patients. We
propose that such patients may be more likely to have further AKI episodes or progress to CKD and further longitudinal
studies are required to investigate this.
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INTRODUCTION
Acute kidney injury (AKI) is a global healthcare concern, occur-
ring in as many as 10–20% of people requiring hospital inpatient
care [1]. AKI is associated with increased mortality, and is a risk
factor for chronic kidney disease (CKD) and end-stage kidney
disease [1]. A major limitation in current clinical practice is that
serum creatinine, used to describe onset and stage of AKI, is a
marker of renal excretory function that does not reliably inform
the type or severity of renal injury, nor the subsequent cellular
responses of damage and repair [2]. Furthermore, serum creati-
nine and estimated glomerular filtration rate (eGFR) are affected
by changes in muscle mass, which occur commonly during hos-
pitalization, and this can result in significant overestimation of
renal recovery [3]. Renal imaging for AKI is currently restricted
to ultrasound, largely performed to exclude urinary tract ob-
struction, and which often adds little to clinical decision-
making. Improved methods of characterizing renal injury at the
time of AKI and more accurately assessing degree of residual
kidney damage are urgently required.
Multiparametric magnetic resonance imaging (MRI) techni-
ques offer the potential to quantify pathophysiological pro-
cesses relevant to AKI non-invasively, and a range of MRI
measures such as longitudinal relaxation time (T1) mapping, ar-
terial spin labelling (ASL) perfusion and total kidney volume
(TKV) can be collected without the use of gadolinium contrast.
By combining multiple MR measures within a single scan ses-
sion a complete picture of the changes in kidney morphology,
microstructure, haemodynamics and oxygenation can be pro-
vided. This enhances interpretation of MRI measures and allows
better understanding of the pathophysiology of the changes as
compared with collecting a single MRI measure alone.
Multiparametric MRI has been applied in humans with CKD [4–
6] and in renal transplantation [7], but to date, the few published
clinical studies using MRI in AKI have used only a single MRI
measure. Dong et al. [8] used renal ASL and showed cortical per-
fusion in AKI was significantly lower than in healthy volunteers
(HVs). Prowle et al. [9] used phase-contrast MRI (PC-MRI) to dem-
onstrate reduced renal artery blood flow in critically ill patients
with AKI compared with HVs. Inoue et al. [10] used blood oxygen
level-dependent (BOLD) MRI to measure R2* in AKI patients, but
the results showed no consistent trends, while Bauer et al. [11]
studied participants with acute tubular necrosis (ATN) and
reported a wide range of R2* values and no significant change in
R2* in response to furosemide.
MRI has been used in animal studies to study experimental
AKI models. Hueper et al. [12] induced moderate and severe is-
chaemia–reperfusion injury (IRI) in a mouse model, and renal
perfusion was measured using ASL at five timepoints between 1
and 28 days following the induction of AKI. Perfusion was de-
creased at Day 7 post-AKI for both the moderate and severe AKI
model, and while this recovered by Day 21 for moderate injury,
it did not recover following severe AKI. In a similar study by the
same group, longitudinal relaxation time (T1), a marker of extra-
cellular tissue fluid, increased following AKI, peaking at Day 7,
and higher values were seen with more severe IRI [13].
Persistent elevations in T1 in the outer stripe of the outer me-
dulla predicted subsequent kidney volume loss at Day 28.
Here, we report a pilot study using multiparametric renal
MRI comprising TKV, T1 mapping, ASL perfusion and BOLD R2*
mapping to assess changes in renal pathophysiology in partici-




Nine adults with AKI Stage 3 (defined using Kidney Disease:
Improving Global Outcomes criteria) of >24 h duration were
recruited from a renal inpatient setting (Royal Derby Hospital,
UK). Participants were excluded if they had pre-existing CKD
(eGFR<60 mL/min/1.73 m2 or renal transplant), AKI due to uri-
nary obstruction, contraindications to MRI or if patients were
deemed not medically stable for transfer to the MRI centre (Sir
Peter Mansfield Imaging Centre, UK). The study was approved
by the East Midlands Research Ethics committee and all partici-
pants gave written informed consent. The study was registered
at ClinicalTrials.gov (NCT03578523).
Participant assessments
Participants were studied at three timepoints: time of AKI (inpa-
tient hospital stay as soon as possible after AKI onset), and as
outpatients at 3 months and 1 year after the AKI episode. At
each timepoint clinical data, measures of renal function and
multiparametric renal MRI were obtained. Clinical data included
demographics, medical history, medication, aetiology of AKI,
blood pressure, height, weight and body mass index (BMI).
Baseline serum creatinine was defined as the most recent stable
serum creatinine prior to hospital admission. Protein-to-
creatinine ratio (PCR) was measured from a single early morn-
ing urine sample (normal defined as <15 mg/mmol). eGFR was
calculated from serum creatinine concentration (enzymatic col-
orimetric assay, Roche Diagnostics, Burgess Hill, UK) using the
CKD Epidemiology Collaboration) formula [14], although eGFR
was not calculated for inpatient measurements when renal
function was not in steady state.
Multiparametric renal MRI
Data acquisition. Multiparametric renal MRI was performed on
a 3T Philips Ingenia scanner (Multi-Transmit, dStream), using
the imaging protocols described previously in a study of HVs
and CKD patients [4, 15]. The primary measures for this study
were TKV, ASL perfusion, T1 mapping and BOLD R2*.
Balanced turbo field echo (bTFE) localizer scans (30 contigu-
ous slices with 1.75  1.75  5 mm resolution collected in a sin-
gle breath hold per orientation) were acquired in three
orthogonal planes for quantification of kidney volume and
planning of the five contiguous coronal oblique slices collected
for multiparametric MRI. All multiparametric MRI data were ac-
quired at end-expiration with a 288 288 mm2 field of view,
3 3 mm2 in-plane resolution and 5 mm slice thickness.
ASL perfusion. Respiratory-triggered flow alternating inver-
sion recovery (IR) ASL data were acquired with in-plane pre-
and post-saturation pulses immediately before and after the la-
belling pulses, and an inversion time (TI) of 1800 ms with
selective (S)/non-selective (NS) thickness of 45/400 mm, and
25 S/NS pairs [15, 16] with a minimum repetition time (TR) of 4 s
between ASL label and control images; if a subject had a respira-
tory cycle length shorter than this, then two respiratory cycles
were waited for between the control/label measures. In addi-
tion, data were acquired across a range of TIs (four S/NS pairs at
300/500/700/900 ms) to assess inflow as well as an M0 scan for
perfusion quantification. The M0 scan was collected with the
same readout parameters as the ASL scan but without the ASL
labelling and using a long TR to ensure full recovery of equilib-
rium magnetization. All data were collected with a spin-echo
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echo-planar-imaging (SE-EPI) readout (SENSE 2.3/TE 27 ms). The
acquisition time for the ASL, inflow and M0 scans was 10 min,
dependent on the subject’s breathing rate.
T1 mapping. A respiratory-triggered IR T1 dataset (TIs: 200/
300/400/500/600/700/800/900/1000/1100/1200/1300/1500 ms, tem-
poral slice spacing 58 ms, minimum TR of 10 s) with fat-
suppressed SE-EPI readout was collected [15] with matched ge-
ometry to the ASL data, to allow perfusion quantification. For
improved corticomedullary differentiation (CMD), a single slice
IR-bFFE (TI: 370/470/570/670/770/870/970/1070/1170/1270/1370/
1470/1670 ms) T1 dataset with high in-plane resolution
(1.5 1.5 mm2) was also acquired. The acquisition time for the
T1 mapping scan was 3 min.
The ASL and T1 data acquisition both used a respiratory trig-
gered scheme [15] to minimize respiratory-induced abdominal
motion between images of differing contrast collected across
the range of TIs. The respiratory trigger was applied at the peak
of inspiration in the respiratory cycle and the image was then
acquired at a constant time following this trigger, during the
flat end-expiration period of the respiratory cycle by introduc-
ing a variable delay, Tv, between the respiratory trigger and the
inversion pulse, which was followed by the TI, thus holding the
time at which all image readouts are collected during end-
expiration at a constant time of TvþTI that was set to 1800 ms.
The minimum TR of the T1 mapping scheme was set to 10 s to
ensure full recovery between inversion pulses.
BOLD data. BOLD R2* data were acquired using a multi-echo
fast field echo (mFFE) scheme (12 echoes, TE1/DTE¼ 5/3 ms,
SENSE2, 25 flip angle). These data were collected in three 16 s
breath holds (with two slices collected per breath hold).
Data analysis. Data analysis followed the techniques previously
outlined in detail in Cox et al. [15]. TKV was computed by manu-
ally tracing the kidney on the coronal bTFE localizer images us-
ing Analyze9VR software (AnalyzeDirect, Overland Park, KS, USA)
and corrected by body surface area (BSA). Multiparametric maps
were collected in the same space for T1, perfusion and R2*, and
maps were computed using in-house software (MATLAB, The
Mathworks Inc., MA, USA). T1 maps were generated by fitting IR
data to generate T1 and M0 maps for the SE-EPI: readout and an
apparent T1 and M0 map for the bFFE readout. Perfusion-
weighted images were computed by realignment and averaging
of S/NS data sets, and subtraction of the averaged NS image
from the S image, to create a single perfusion-weighted (DM)
map. DM, inflow, M0 and T1 maps were then used in a kinetic
model to calculate tissue perfusion maps [15]. The mFFE data
were fit to form R2* maps by computing the log of the exponen-
tial signal decay.
Renal cortex and renal medulla masks were formed from the
T1 maps, using a histogram of T1 values within both kidneys to de-
fine a T1 threshold for segmentation. Each mask was applied to
each multiparametric map (T1, perfusion and R2*), generating a his-
togram of each multiparametric MRI measure in the cortex and
medulla [15] to which a Gaussian curve was fit and the mode and
full-width-at-half-maximum computed. Subsequently, the CMD in
each measure was computed. Since no significant difference in
multi-parametric measures was observed between right and left
kidneys, the mean of both kidneys was used in analyses.
Statistical analysis
A Shapiro–Wilk normality test was applied to clinical and MRI
measures. Normal data are expressed as mean 6 standard
deviation (SD) and non-parametric data as median [interquar-
tile range (IQR)].
Clinical data. Data were analysed using IBM SPSS version 25.
Friedman and Wilcoxon signed-rank tests were used to test for
significance.
MRI data. Narrative descriptions outline MRI measures across
individual participants. For group statistical analysis, Prism 6
(GraphPad Software, Inc., La Jolla, CA, USA) was used.
Significant differences between timepoints were assessed using
a one-way analysis of variance (ANOVA) with Bonferroni correc-
tion for multiple comparisons, with P< 0.05 considered statisti-
cally significant and a subsequent post hoc t-test analysis
between timepoints. Participants with missing data were ex-
cluded from the group analyses comparing timepoints.
RESULTS
Participant demographics
Nine participants with AKI underwent initial assessment and
scanning, and seven attended both 3-month and 1-year follow-
up assessments (two participants declined follow-up). Inpatient
MRI scanning was performed at a median (IQR) of 6 (5) days af-
ter peak serum creatinine value. Participant characteristics are
summarized in Table 1. All participants had AKI Stage 3 and
two required acute renal replacement therapy, which was inter-
mittent haemodialysis. Five of the nine AKI cases were associ-
ated with sepsis.
Clinical measures
Renal function had begun to recover in most patients at the first
MRI scan; serum creatinine was significantly lower than at peak
AKI but was significantly higher than baseline (pre-AKI). Table 2
summarizes clinical variables across the timepoints of the
study for the seven participants who took part in all visits.
During outpatient follow-up, renal function improved with all
participants recovered to eGFR values of >60 mL/min/1.73 m2 at
3 months and 1 year, and corresponding serum creatinine val-
ues similar to baseline (pre-AKI) values (Figure 1A). Proteinuria
was present in seven of the nine participants at the time of their
inpatient MRI scan and while this did resolve in some patients,
at 3 months three of seven patients displayed persistent pro-
teinuria, and one patient had proteinuria (urine PCR 148 mg/
mmol) at 1 year.
MRI measures
Individual patient measures. Figure 1B–D shows each partici-
pant’s MRI measures of TKV, cortical perfusion and cortical and
medullary T1 collected at the three timepoints. Reference
ranges from comparator HV (61 6 25 years, eGFR 92 6 12 mL/
min/1.73 m2) and CKD (61 6 24 years, eGFR 39 6 14 mL/min/
1.73 m2) groups are also shown by Buchanan et al. [4].
Importantly, these data were collected using the same data ac-
quisition measures and data analysis procedures as for the AKI
data. Individual data are shown for all nine patients at time of
AKI (Figure 1).
TKV. At the time of AKI, seven participants had TKVs
higher than the HV range (396 6 99 mL) (Figure 1B). TKV de-
creased at 3 months post-AKI in all participants and further
decreased at 1 year post-AKI, although it remained above the
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range expected in HVs in two participants. Conversely, two
patients had TKVs at 1-year that fell below that of HVs into
the CKD range (322 6 114 mL).
Longitudinal relaxation time, T1. At time of AKI, cortical T1 val-
ues were higher than the HV range (1432 6 87 ms) in all partici-
pants, and higher than the expected range in CKD
(1574 6 74 ms) in seven participants using the SE-EPI readout
(Figure 1Di) and all participants using the bFFE readout (Figure
1Dii). Medullary T1 values at time of AKI were higher than the
CKD range (1754 6 50 ms) in all participants for both image read-
outs. Compared with the time of AKI, T1 values decreased at 3
months and further decreased at 1 year post-AKI, although val-
ues did not fall to the HV range in all participants. As expected,
there was a strong correlation between individual SE-EPI and
bFFE T1 measures for both renal cortex (R¼ 0.94, P< 0.001) and
medulla (R¼ 0.81, P< 0.001). The higher in-plane resolution of
the bFFE T1 maps provided improved delineation of changes in
renal cortex and medulla (Figure 2); these images also illustrate
Table 1. Characteristics of study population
Number of patients N¼ 9 N¼ 7
Age, years 46 6 17 44 6 18
Gender (male:female) 5:4 4:3
BMI, kg/m2 30.2 6 6.1 30.9 6 6.8
Baseline eGFR, mL/min/1.73 m2 91 6 22 (range 68–133) 91 6 23 (range 68–133)
Baseline serum creatinine, mmol/L 81 6 23 82 6 23
Admission serum creatinine, mmol/L 349 6 201 330 6 119
Peak serum creatinine, mmol/L 531 6 250 449 6 215
AKI Stage 3, % 9 (100) 7 (100)
Highest C-reactive protein during admission 78 (IQR 273) 78 (IQR 150)
Lowest systolic blood pressure during index ad-
mission, mmHg
111 6 9 (range 100–125) 109 6 9 (range 100–123)
Acute RRT, % 2 (22) 1 (14)
Comorbidity, %
Diabetes mellitus 3 (30) 3 (43)
Hypertension 3 (30) 1 (14)
Cardiovascular disease 0 0
Aetiology of AKI, %
Sepsis (%) 5 (56) 4 (57)
Hypovolaemia/hypoperfusion (%) 2 (22) 2 (29)
Tubulointerstitial nephritis (%) 1 (11) 1 (14)
Paracetamol overdose (%) 1 (11) 0
Medications prior to index hospital admission
ACEi/ARB (%) 3 (33.3) 2 (29)
Diuretic (%) 1 (11) 1 (14)
CCB (%) 3 (33.3) 2 (29)
Average number of anti-hypertensive medica-
tions per patient, median (IQR)
0.7 (1.5) 0.6 (2)
Nine participants (n¼9) with AKI underwent initial assessment and scanning, and seven (n¼7) attended both 3-month and 1-year follow-up assessments (two partici-
pants declined follow-up). Normally distributed variables are presented as mean 6 SD. Non-normally distributed variables are presented as median (IQR). Categorical
variables are presented as a percentage (number). ACEi, angiotensin-converting enzyme inhibitor; ARB, angiotensin-receptor blocker; CCB, calcium channel blocker;
RRT, renal replacement therapy.













Serum creatinine, mmol/L 82 6 23a 449 6 215a 159 6 61a 85 6 17a 81 6 16a
eGFR, mL/min/1.73 m2 91 6 23 Not calculated 89 6 22 99 6 18
Systolic blood pressure,
mmHg
109 6 9 142 6 21 128 6 16 134 6 15
C-reactive protein, mg/L 78 (150) 2 (8) 1.6 (5)
UPCR, mg/mmol 29 6 49 18 6 62 9 (134)
Recurrent AKI 0 0
Hospital readmission 0 0
Normally distributed variables are presented as mean 6 SD. Non-normally distributed variables are presented as median (IQR).
aThere was a significant change in serum creatinine over time (Friedman test), with a Wilcoxon signed rank test showing a significant difference between creatinine at
peak AKI compared with all subsequent time measures (P<0.01), creatinine at first MRI scan (inpatient) and creatinine at 3 months post-AKI (P¼ 0.004) and 1 year
(P¼0.005). No significant differences were seen between creatinine measures at 3 months and 1 year post-AKI (P¼ 0.2). UPCR, urinary protein to creatinine ratio.










































































































































































































































































































T1 SE-EPI medulla (ms)
FIGURE 1: (A) Serum creatinine levels for each participant prior to AKI, at time of peak AKI, and at the time of each inpatient, 3-month post-AKI and 1-year post-AKI
MRI scan. MRI measures collected at the three scan sessions—inpatient, 3-month post-AKI and 1-year post-AKI for (B) TKV and TKV corrected for BSA, (C) cortex perfu-
sion and (D) T1 of the renal cortex and renal medulla for (i) the SE-EPI and (ii) bFFE image readout, and (iii) the correlation between bFFE and SE-EPI results. Grey and
pink bands show the range of values in HV and CKD cohorts, respectively. Note, the range of renal cortex T1 in CKD [1D and 3D pink band] is elevated compared with
the HV range [D and 3D grey band], whilst medulla T1 in CKD falls within the HV range.
FIGURE 2: Example bFFE T1 maps through the long-axis of the kidney collected at the inpatient MRI scan and subsequently at 3 months and 1 year post-AKI. There is a
clear lack of CMD for the inpatient T1 map, with T1 values of both the renal cortex and medulla being long. A reduction in the T1 of renal cortex and medulla is seen at 3
months and 1 year post-AKI, together with enhanced CMD. Data shown for (A) Subject 2 and (B) Subject 5, who had a significant drop in TKV.
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the reduction of TKV from time of AKI to the 3-month and 1-
year timepoints, particularly evident in Subject 5 (Figure 2B).
Cortical perfusion. Cortical perfusion as measured by ASL
(n¼ 5) was lower than the HV range (200 6 56 mL/100 g/min) at
time of AKI; perfusion improved but remained low at 3 months
post-AKI, returning to the HV range in only two participants at 1
year post-AKI (Figure 1C).
Group comparisons. Figure 3 shows the MRI data grouped
across the seven participants who attended all scan visits.
TKV. A significant reduction in both TKV (Figure 3Ai) and
BSA corrected TKV (Figure 3Aii) was observed across time
(inpatient: 553 6 196 mL, 3 months: 421 6 152 mL, 1 year:
397 6 145 mL, P¼ 0.01), post hoc comparisons revealed a signifi-
cant difference between inpatient and 3-month scan (P¼ 0.008).
There was no significant difference between scans at 3 months
and 1 year post-AKI (P¼ 0.1).
Longitudinal relaxation time, T1. A significant decrease in SE-EPI
(Figure 3C) and bFFE (Figure 3D) T1 values was found over time
(T1 cortex bFFE: inpatient: 1775 6 55 ms, 3 months: 1606 6 74 ms,
1 year: 15146 69 ms, P< 0.001; T1 medulla bFFE: inpatient:
1954 6 38 ms, 3 months: 1862 6 29 ms, 1 year: 1789 6 99 ms,
P< 0.01). Post hoc t-tests showed differences between time of AKI
and 3-month scan for both renal cortex and medulla (P¼ 0.001
for SE-EPI and P< 0.001 for bFFE). Between 3 months and 1 year
post-AKI there was a significant reduction in cortical T1 (P¼ 0.047
for SE-EPI and P¼ 0.024 for bFFE); however, no significant differ-
ence was found in the medulla for either readout, with a wider
range of T1 values. The CMD significantly increased (became
more negative) over time for the bFFE T1 measure (P¼ 0.02), al-
though this trend was not significant (P¼ 0.058) for the SE-EPI T1
maps, likely due to the reduced in-plane spatial resolution of the
SE-EPI data to define the cortex and medulla.
Cortical perfusion. Cortical perfusion increased significantly
across time (inpatient: 65 6 33 mL/100 g/min, 3 months:
106 6 50 mL/100 g/min, 1 year: 147 6 66 mL/100 g/min, P¼ 0.001,
Figure 3B), with a significant increase in perfusion between
time of AKI and 1-year follow-up scan (P¼ 0.02), but no signifi-
cant difference between time of AKI and 3-month scan, or 3-
month and 1-year scan (P¼ 0.06 for each). Acceptable quality
BOLD R2* data were only achieved in four patients due to mo-
tion artefacts during the breath-hold scan. Subjects for whom
data quality was acceptable are shown in Figure 3E; BOLD R2*










































































































































































































































P = 0.01 P = 0.058
P = 0.08 P = 0.4 P = 0.4
P = 0.001P = 0.01 P = 0.01


































Example in-patient maps 
FIGURE 3: MRI results grouped across the seven participants who attended all visits. Data shown for (A) TKV [(i) TKV and (ii) BSA corrected TKV]; (B) cortex perfusion;
(C) SE-EPI T1 values for the renal cortex, medulla and CMD; (D) bFFE T1 values for the renal cortex, medulla and CMD; (E) R2* measured in the renal cortex, medulla and
CMD. P-values are shown for a repeated measures ANOVA (or Friedmann test for non-parametric data) across the three timepoints. Post hoc t-tests are shown as
**P<0.01 and *P<0.05.
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DISCUSSION
In this study, we have performed multiparametric MRI in nine
patients with AKI to non-invasively quantify longitudinal
changes in renal pathophysiology. In all participants, serum
creatinine recovered to baseline levels. At time of AKI, MRI data
showed increased TKV, increased cortex/medulla T1 and re-
duced cortical perfusion compared with the expected ranges in
HVs and people with CKD. TKV and T1 values decreased over
time after AKI and returned to expected values in most but not
all patients by 1 year. Cortical perfusion improved to a lesser ex-
tent and remained below the expected range in the majority of
patients by 1 year post-AKI.
Clinically, there is a need to develop new methods to better as-
sess the nature and severity of renal injury across the wide spec-
trum of clinical scenarios and patient groups in which AKI
develops. Furthermore, chronic impairment of renal function after
AKI often goes undetected due to the insensitivity of eGFR, as well
as lack of testing and follow-up. Considerable efforts have been di-
rected towards the development of plasma and urine biomarkers
for earlier diagnosis compared with serum creatinine, or to assess
risk of progression or lack of recovery, although few are in wide-
spread clinical use [17]. Quantitative MRI provides ‘imaging bio-
markers’ sensitive to pathophysiological processes occurring in
AKI, including changes in tissue microstructure, cortical perfusion
and oxygenation [18–20]. This combination of measures may ad-
dress important clinical challenges, for example, identifying mech-
anisms of renal injury and assessment of AKI severity, measuring
the time-course of resolution of AKI-induced abnormalities, differ-
entiating between those who recover completely versus those who
are left with chronic damage, and improving prognostic assess-
ment of those at risk of clinically significant CKD progression. To
date, the use of quantitative MRI to study AKI has been limited [8–
11]; a multiparametric approach has not previously been
attempted, nor has MRI been used to assess the recovery phase of
AKI. Here, we used multiparametric MRI to study the human renal
cortex and medulla at the time of AKI, and to describe changes
during recovery.
We observed that TKV at the time of AKI was markedly in-
creased compared with the HV range. Clinically, ultrasound-mea-
sured kidney size (reported as kidney length) is used to distinguish
AKI from the diagnosis of CKD, which is associated with small kid-
neys. Less commonly, ultrasound can identify increased kidney
size in some AKI such as infiltrative diseases, renal vein thrombo-
sis and acute glomerulonephritis [21], but these causes of AKI were
not present in our study. The observed increase in TKV was cou-
pled with large increases in renal cortex and medulla T1, notably
higher than for CKD in which T1 is elevated compared with HVs
[4]. T1 measures were consistent across SE-EPI and bFFE measures,
with the higher in-plane spatial resolution bFFE scan providing su-
perior visual definition of cortex and medulla (to achieve as high
spatial resolution for the SE-EPI acquisition, the echo time would
become limiting). The pronounced increase in medulla and cortex
T1 at the inpatient AKI scan is suggestive of oedema and/or inflam-
mation of the renal parenchyma, which may also explain why
TKV increased [22].
During recovery, TKV and T1 measures declined, consistent
with resolution of oedema or inflammation from the acute
phase of AKI. In most participants, TKV returned to the HV
range by 1 year, although TKV remained elevated in two partici-
pants. Conversely, in two other participants, TKV fell to a value
below the CKD range. This finding may suggest chronic, sub-
clinical renal damage, consistent with animal studies associ-
ated with kidney volume loss proportionate to AKI severity and
chronic damage [13]. However, this cannot be concluded with
certainty as TKV was not measured in our patients prior to the
AKI episode. Furthermore, some participants had persistent ele-
vations in cortex and medullary T1 after 1 year, which may
again reflect chronic, subclinical damage.
We observed reduced cortical perfusion at the time of AKI in
comparison with the HV range. Reduced perfusion is regarded as a
key initiating process in many forms of AKI (e.g. volume depletion,
reduced cardiac output, systemic vasodilation in sepsis or renal va-
soconstriction in hepato-renal syndrome) [23]. Our observation of
reduced cortical perfusion in participants with predominantly sep-
sis and hypovolaemia-associated AKI is in agreement with previ-
ous human and animal studies using ASL. Dong et al. [8] used renal
ASL to study 13 participants at the time of AKI and showed that re-
nal perfusion in this group was significantly lower (223–392 mL/
100 g/min) than for HVs (357–426 mL/100 g/min). Hueper et al. [12]
showed a decrease in perfusion in a mouse model of IRI, with
greater reductions seen in severe AKI that persisted to 28 days.
Prowle et al. [9] used PC-MRI to demonstrate a significant reduction
in renal artery blood flow [median 244 (165–662) mL/min/m2] in 10
adults with established septic AKI compared with HVs (525 mL/
min/m2), a magnitude of reduction in blood flow consistent with
our findings for renal perfusion. In our study, perfusion increased
post-AKI but remained in the CKD range at 1 year post-AKI in
some participants. We speculate this represents vascular rarefac-
tion and/or nephron loss and may indicate those participants
more likely to have a further AKI episode or progress to CKD.
The shortened BOLD R2* is likely a result of decreased trans-
verse relaxation rate (R2) due to inflammation, as shown in AKI in
mice [24]. Inoue et al. [10] assessed BOLD in 23 AKI Stages 1–3
patients in comparison with HVs and CKD patients, but their
results showed no consistent trends, which they attributed to the
range of interstitial oedema and renal hypoxia in AKI. Bauer et al.
[11] used BOLD R2* to study nine participants with ATN-induced
AKI, assessed at baseline and after administration of furosemide.
A wide range of R2* values was found for the AKI group and no sig-
nificant change in R2* in response to furosemide.
In our analysis, MRI measures in AKI participants were com-
pared with a CKD and HV group. The AKI participants age range
was lower (46 6 17 years), although overlapping with the HV and
CKD comparator groups (61 6 25 years). Any age dependence
could result in the reference range HV and CKD perfusion values
being lower and T1 values being higher [25], but this effect is
likely to be minor and would result in more conservative esti-
mates of difference.
Collection of PC-MRI (and a non-contrast-enhanced MR an-
giogram for planning) and diffusion-weighted imaging multi-
parametric scans were secondary measures included towards
the end of the scan session, but these data were not collected or
had to be discarded due to poor quality. There were challenges
associated with scanning AKI participants, especially during
their inpatient stay, due to the need to lie supine for a long pe-
riod and perform breath-hold scans. In future, the use of re-
cently available compressed sensing for body MRI [26], allowing
data to be acquired in shorter scan periods and significantly
shorter breath-hold lengths, will be explored. In addition, the
use of a respiratory navigator rather than the respiratory bel-
lows for respiratory gating will be trialled, as patients found the
latter to be uncomfortable, limiting acquisition of the perfusion
data at the inpatient scan. Furthermore, having evaluated the
optimal measures for use in research studies, we envisage a
smaller subset of the key measures would be used for future
clinical application. A further limitation of this study is the
small participant number due to the challenges associated with
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recruiting patients during acute illness. This resulted in some
bias in favour of patients with less severe illness, as patients re-
quiring intensive care management were not studied.
In conclusion, we have shown changes in multiparametric
renal MRI measures of kidney volume, T1 and perfusion outside
the healthy range at time of AKI. These MRI measures improved
over the 1 year follow-up but did not return to the HV range in
all participants, despite all achieving biochemical recovery.
These results provide essential pilot data to inform the design
of future larger studies.
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